PD-1 Antibody-based Therapy With Concurrent RT for Early-stage NKTCL
Plain-language summary
This trial is testing EBV-specific T cells (immune cells trained to attack Epstein-Barr virus in lymphoma cells) for patients with extranodal NK/T-cell lymphoma (ENKTL) who have been newly diagnosed and have not yet received treatment. This is a Phase 2 trial, which means researchers are studying how well the treatment works and monitoring for side effects. Patients are randomly assigned to different treatment groups. This trial does not currently have sites in the United States. The trial is currently recruiting patients.
Who can join (key eligibility)
- Age 18 Years or older
- Newly diagnosed, not yet treated
- Must be well enough for treatment (adequate performance status)
Final eligibility is determined by the trial team. This list is a starting point only.
What's being tested
PD-1 antibody (DRUG): Administration of PD-1 mAb will start on Day 1 of radiotherapy (C1D1) at a dose of 200 mg via intravenous infusion over 30 minutes or longer, once every 3 weeks, cycle 1 - cycle 6 | radiotherapy (RADIATION): Concurrent standard involved-site radiotherapy (ISRT) | Chidamide (DRUG): The dosage of chidamide will follow a dose-escalation design: 20 mg twice weekly (biw) in the first stage, then escalated to 30 mg biw, using the Bayesian Optimal Interval (BOIN) design to determine the recommended dose, followed by dose expansion in the second stage, every 3 weeks, cycle 4 - cycle 6. | golidocitinib (DRUG): Golidocitinib will be administered at a dose of 150 mg once daily (qd), every 3 weeks, cycle 4 - cycle 6.
PD-1 antibody, radiotherapy, Chidamide, golidocitinib
- Treatment length
- Ask the trial team for details
- Visit frequency
- Ask the trial team for details